The abstract is read at the publisher; the summary is JClub's.
Astragaloside II (ASII) is predicted to bind dengue virus NS1 and, in HMEC-1 cells, preserves relative trans-endothelial electrical resistance near control despite NS1 lowering it to 0.56 (P < 0.001).
- Why it matters: Severe dengue involves endothelial barrier leakage driven by NS1, yet there is no approved antiviral that targets NS1 to prevent hyperpermeability.
- What they did: A deep learning model using chemical fingerprints and protein sequences prescreened 177 natural compounds across NS1 from four dengue serotypes, then docked ASII to the NS1 dimer. In HMEC-1, ASII was tested at 10–30 {micro}g/mL, and a competitive ELISA measured dose-dependent inhibition of NS1-heparan sulfate binding (IC50 51.12 {micro}g/mL; 95% CI 47.91–56.24 {micro}g/mL).
- The result: ASII maintained resistance close to control without detectable cytotoxicity, did not reduce NS1 internalization, and inhibited heparan sulfate binding by only 8–26% at protective doses, implying a mechanism that remains unresolved.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.